BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will present a LibiGel
clinical update at the 2010 Annual Meeting of the International Society
for the Study of Women’s Sexual Health (ISSWSH), being held from
February 18-20, 2010 in St. Petersburg, Florida.
“Low Cardiovascular
Event Rate in Post-menopausal Women with Increased Cardiac Risk:
Findings from the Ongoing Blinded LibiGel (testosterone gel)
Cardiovascular and Breast Cancer Safety Study”
Michael C. Snabes, MD, PhD, BioSante’s vice president of clinical
development, will give a presentation entitled, “Low Cardiovascular
Event Rate in Post-menopausal Women with Increased Cardiac Risk:
Findings from the Ongoing Blinded LibiGel (testosterone gel)
Cardiovascular and Breast Cancer Safety Study,” on Saturday February 20,
2010.
BioSante is in Phase III development of LibiGel for the treatment of
hypoactive sexual desire disorder (HSDD) in menopausal women under an
FDA approved SPA (Special Protocol Assessment). BioSante is enrolling
women in three Phase III clinical studies with a new drug application
(NDA) planned for mid-2011. “There still is no FDA approved
pharmaceutical product for the treatment of HSDD and it is clear from
the extensive off-label use of drugs for HSDD that women need an
approved therapy. We believe LibiGel can be first product to market for
this unmet medical need.” said Dr. Snabes.
The annual ISSWSH conference brings together physicians, other
healthcare providers, researchers, investors and companies in a meeting
dealing with all issues related to women’s sexual health including HSDD.
Study shows AI can predict prognosis in triple-negative breast cancer